• Je něco špatně v tomto záznamu ?

Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor

K. Trtková, L. Pašková, N. Matiješčuková, Z. Kolář

. 2010 ; 7 (2) : 79-90.

Jazyk angličtina Země Nizozemsko

Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12027189

Grantová podpora
NR9475 MZ0 CEP - Centrální evidence projektů
NS10262 MZ0 CEP - Centrální evidence projektů

Signaling through the androgen receptor (AR) plays a critical role in prostate cancer progression. The AR is a classical nuclear receptor (NR) providing a link between signaling molecule and transcription response. Histone deacetylase inhibitors (HDACI) have antiproliferative and proapoptotic effects on prostate cancer cells and their implication in silence AR signaling may have potential therapeutic use. We aimed to study the inhibitory effects of the corepressor SMRT (Silencing Mediator for Retinoid and Thyroid hormone receptors) which forms a complex together with nuclear receptor corepressor (N-CoR) and with histone deacetylase 3 (HDAC3) on AR activity. The androgen-sensitive prostate cancer cell line LNCaP and androgen-insensitive prostate cancer cell line C4-2 both AR-positive, and androgen-insensitive DU145 and PC3 prostate cancer cell lines were treated with two HDACIs, sodium butyrate (NaB) and/or trichostatin A (TSA). We amplified immunoprecipitated DNA by conventional PCR and in the following step we used the chromatin immunoprecipitation (ChIP) analysis coupled with quantitative PCR for monitoring NaB induced formation of AR-SMRT/N-CoR complex binding on the PSA promoter. The co-immunoprecipitation assay revealed increase in AR-SMRT formation in NaB treated cells. Simultaneously, the Western blot analysis showed a significant decrease in AR protein expression. Furthermore, we estimated the reduced presence of HDAC2 and HDAC3 proteins by NaB and TSA treatment in AR-negative DU145 cell line. In conclusion, the inhibitory effect of NaB on AR gene expression seems to be specific and unique for prostate cancer AR-positive cell lines and corresponds with its ability to stimulate AR-SMRT complex formation. We suggest that AR and SMRT/N-CoR corepressors may form a stable complex in vitro and NaB may facilitate the interaction between AR nuclear steroid receptor and SMRT corepressor protein.

Formation of AR-SMRT complex and its binding to PSA promoter in prostate cancer cells treated with natural histone deacetylases inhibitor

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12027189
003      
CZ-PrNML
005      
20160408164106.0
007      
ta
008      
120816s2010 ne f 000 0eng||
009      
AR
024    7_
$a 10.3233/cbm-2010-0150 $2 doi
035    __
$a (PubMed)21178266
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Smešný Trtková, Kateřina, $u Laboratory of Molecular Pathology and Department of Pathology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. trtkova@post.cz $d 1965- $7 xx0143535
245    10
$a Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor / $c K. Trtková, L. Pašková, N. Matiješčuková, Z. Kolář
246    33
$a Formation of AR-SMRT complex and its binding to PSA promoter in prostate cancer cells treated with natural histone deacetylases inhibitor
520    9_
$a Signaling through the androgen receptor (AR) plays a critical role in prostate cancer progression. The AR is a classical nuclear receptor (NR) providing a link between signaling molecule and transcription response. Histone deacetylase inhibitors (HDACI) have antiproliferative and proapoptotic effects on prostate cancer cells and their implication in silence AR signaling may have potential therapeutic use. We aimed to study the inhibitory effects of the corepressor SMRT (Silencing Mediator for Retinoid and Thyroid hormone receptors) which forms a complex together with nuclear receptor corepressor (N-CoR) and with histone deacetylase 3 (HDAC3) on AR activity. The androgen-sensitive prostate cancer cell line LNCaP and androgen-insensitive prostate cancer cell line C4-2 both AR-positive, and androgen-insensitive DU145 and PC3 prostate cancer cell lines were treated with two HDACIs, sodium butyrate (NaB) and/or trichostatin A (TSA). We amplified immunoprecipitated DNA by conventional PCR and in the following step we used the chromatin immunoprecipitation (ChIP) analysis coupled with quantitative PCR for monitoring NaB induced formation of AR-SMRT/N-CoR complex binding on the PSA promoter. The co-immunoprecipitation assay revealed increase in AR-SMRT formation in NaB treated cells. Simultaneously, the Western blot analysis showed a significant decrease in AR protein expression. Furthermore, we estimated the reduced presence of HDAC2 and HDAC3 proteins by NaB and TSA treatment in AR-negative DU145 cell line. In conclusion, the inhibitory effect of NaB on AR gene expression seems to be specific and unique for prostate cancer AR-positive cell lines and corresponds with its ability to stimulate AR-SMRT complex formation. We suggest that AR and SMRT/N-CoR corepressors may form a stable complex in vitro and NaB may facilitate the interaction between AR nuclear steroid receptor and SMRT corepressor protein.
650    _2
$a butyráty $x metabolismus $x farmakologie $x terapeutické užití $7 D002087
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a histondeacetylasa 2 $x metabolismus $7 D056464
650    _2
$a inhibitory histondeacetylas $x terapeutické užití $7 D056572
650    _2
$a histondeacetylasy $x metabolismus $7 D006655
650    _2
$a lidé $7 D006801
650    _2
$a kyseliny hydroxamové $x metabolismus $x farmakologie $x terapeutické užití $7 D006877
650    _2
$a imunoprecipitace $7 D047468
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a korepresor 2 jaderného receptoru $x genetika $x metabolismus $7 D056985
650    _2
$a nádory prostaty $x farmakoterapie $x genetika $x metabolismus $7 D011471
650    _2
$a vazba proteinů $x genetika $7 D011485
650    _2
$a androgenní receptory $x genetika $x metabolismus $7 D011944
650    _2
$a časové faktory $7 D013997
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pašková, Lenka $u Laboratory of Molecular Pathology and Department of Pathology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $7 xx0138057
700    1_
$a Matiješčuková, Natálie $u Laboratory of Molecular Pathology and Department of Pathology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Kolář, Zdeněk, $u Laboratory of Molecular Pathology and Department of Pathology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $d 1953- $7 jn20000710256
773    0_
$w MED00173146 $t Cancer biomarkers section A of Disease markers $x 1875-8592 $g Roč. 7, č. 2 (2010), s. 79-90
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21178266 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120816 $b ABA008
991    __
$a 20160408163828 $b ABA008
999    __
$a ok $b bmc $g 949231 $s 784535
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 7 $c 2 $d 79-90 $i 1875-8592 $m Disease markers. Section A, Cancer Biomarkers $n Cancer Biomark $x MED00173146
GRA    __
$a NR9475 $p MZ0
GRA    __
$a NS10262 $p MZ0
LZP    __
$b NLK112 $a Pubmed-20120816/11/02

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...